Edison International Common Stock vs Cassava Sciences Inc — how do they compare? Edison International Common Stock trades at $54.43 (market cap $20.94B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Edison International Common Stock is far larger — about 531.5× Cassava Sciences Inc's market cap, and Edison International Common Stock pays a 6.45% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edison International Common Stock for 0 Days and Cassava Sciences Inc for 37 Days on average.
| EIX | FLNA | |
|---|---|---|
Market Cap | $20.94B | $39.40M |
Volume | 4,419,339 | 759,018 |
Sector | Utilities | Health |
52-Week High | $80.38 | $4.64 |
52-Week Low | $51.47 | $0.68 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $64.32B | -$43.28M |
Dividend Yield | 6.45% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Edison International is the parent company of Southern California Edison, an electric utility that supplies and delivers electricity across Southern California. It also owns Trio, an energy advisory business.
Read more on EIX →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →